{"id":50937,"topic":"peptides","source":"Sohu","title":"肽盛生物获A轮投资 - Sohu","url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","url_hash":"caaece82f8d85b6871708869f22267f1755a98a1","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPYjZVa18yOFFjc1h3UU9fMWE4elRnMEt5Z1h2Rm5QODR4Q2ZDSW4zb2tWc2JfTVI5dS1SeWZYWTVReVczUXpjaWlCUjVGaWpSdDIycXNHeHNnTmM5ckN6NmF4QURwV2FEY1doM01GWWcyaDJlLWszZUsxRmstaEk4cTlQT0dSdjFE?oc=5\" target=\"_blank\">肽盛生物获A轮投资</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","content":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶向递送肽和透皮递送肽等）的发现、筛选、优化CRO服务。\n此次A轮融资将有助于肽盛生物进一步扩大其多肽库规模，优化技术平台，并加速全球市场的拓展。肽盛生物的创新能力及在多肽药物领域的独特优势，吸引了安士启源医药投资与横琴金投的青睐。","image_url":"https://q8.itc.cn/q_70/images03/20260801/93a2f6f6eeec4d5fb79aa73ecb1e7d92.jpeg","lang":"zh","published_at":"2026-07-31T20:08:00+00:00","fetched_at":"2026-07-31T21:15:11+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}},"news_item":{"id":50937,"canonical_url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source_url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","title":"肽盛生物获A轮投资 - Sohu","source_name":"Sohu","author":null,"published_at":"2026-07-31T20:08:00+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPYjZVa18yOFFjc1h3UU9fMWE4elRnMEt5Z1h2Rm5QODR4Q2ZDSW4zb2tWc2JfTVI5dS1SeWZYWTVReVczUXpjaWlCUjVGaWpSdDIycXNHeHNnTmM5ckN6NmF4QURwV2FEY1doM01GWWcyaDJlLWszZUsxRmstaEk4cTlQT0dSdjFE?oc=5\" target=\"_blank\">肽盛生物获A轮投资</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","full_text":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶向递送肽和透皮递送肽等）的发现、筛选、优化CRO服务。\n此次A轮融资将有助于肽盛生物进一步扩大其多肽库规模，优化技术平台，并加速全球市场的拓展。肽盛生物的创新能力及在多肽药物领域的独特优势，吸引了安士启源医药投资与横琴金投的青睐。","excerpt":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 335 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"肽盛生物获A轮投资 - Sohu","url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","source":"Sohu","date":"2026-07-31T20:08:00+00:00","content":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶向递送肽和透皮递送肽等）的发现、筛选、优化CRO服务。\n此次A轮融资将有助于肽盛生物进一步扩大其多肽库规模，优化技术平台，并加速全球市场的拓展。肽盛生物的创新能力及在多肽药物领域的独特优势，吸引了安士启源医药投资与横琴金投的青睐。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 335 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/50937","export_markdown":"/api/items/50937/export?format=markdown","export_json":"/api/items/50937/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"formats":{"full":{"id":50937,"title":"肽盛生物获A轮投资 - Sohu","url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"Sohu","author":null,"published_at":"2026-07-31T20:08:00+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","full_text":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶向递送肽和透皮递送肽等）的发现、筛选、优化CRO服务。\n此次A轮融资将有助于肽盛生物进一步扩大其多肽库规模，优化技术平台，并加速全球市场的拓展。肽盛生物的创新能力及在多肽药物领域的独特优势，吸引了安士启源医药投资与横琴金投的青睐。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 335 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}},"actions":{"read":"/item/50937","export_markdown":"/api/items/50937/export?format=markdown","export_json":"/api/items/50937/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"}},"digest":{"id":50937,"title":"肽盛生物获A轮投资 - Sohu","url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"Sohu","topic":"peptides","published_at":"2026-07-31T20:08:00+00:00","excerpt":"肽盛生物获A轮投资 2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。 肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 335 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"肽盛生物获A轮投资 - Sohu","subtitle":"Sohu · 2026-07-31","summary":"肽盛生物获A轮投资 2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。…","badges":["quality:high"],"links":{"read":"/item/50937","original":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"quality_warning":null},"export":{"title":"肽盛生物获A轮投资 - Sohu","url":"https://m.sohu.com/a/1057387588_115035?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶…","source":"Sohu","date":"2026-07-31T20:08:00+00:00","content":"肽盛生物获A轮投资\n2026年7月30日，深圳肽盛生物科技有限公司（简称“肽盛生物”）宣布完成A轮融资。本轮融资由安士启源医药投资与横琴金投联合投资，具体融资金额未披露。\n肽盛生物是一家专注于多结构创新实体多肽化合物库的提供商。公司基于独创的“复杂结构多肽构建技术”，成功构建了集合多肽结构多样性和序列多样性的实体多肽库。围绕该多肽库，肽盛生物打造了全流程多肽药物发现、筛选、优化技术平台，为全球生物医药公司提供活性多肽（包括医美活性肽、靶向递送肽和透皮递送肽等）的发现、筛选、优化CRO服务。\n此次A轮融资将有助于肽盛生物进一步扩大其多肽库规模，优化技术平台，并加速全球市场的拓展。肽盛生物的创新能力及在多肽药物领域的独特优势，吸引了安士启源医药投资与横琴金投的青睐。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1057387588_115035%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 335 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 335 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":335,"summary_length":221,"usable_text_length":335,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":335,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}